Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

← Back to the feed

Procavea Biotech AG

History from 15 Feb 2024

UID
CHE-178.079.086
Legal form
AG
Canton
ZH
Founded
15 Feb 2024
Amount raised
not in the SHAB
Lead investor
not in the SHAB
Nominal capital · CHFCHF 160k
40k80k120k160k9 Sep 2026 · CHF 160k
  • shares

Record

  1. SHAB published 20 Feb 2024 · legal date 15 Feb 2024

    Company formed

    Founded 15 Feb 2024

    SHAB HR01-1005965253 ↗

  2. SHAB published 9 Sep 2026 · legal date 26 Aug 2026

    Capital increase

    Likely financing

    Paid in cash

    Nominal capital
    100’000 → 160’000
    Shares
    100’000 → 160’000
    New shares, % of post-step shares
    37.5% (60’000 new)

    Aktienkapital neu: CHF 160'000.00 [bisher: CHF 100'000.00]. Liberierung Aktienkapital neu: CHF 160'000.00 [bisher: CHF 100'000.00]. Aktien neu: 160'000 Namenaktien zu CHF 1.00 [bisher: 100'000 Namenaktien zu CHF 1.00].

    From the SHAB entry · German original, person names removed · not an official copy · full entry ↗
    • The company was founded less than six years before this capital increase.+0.5
    • The company's purpose describes technology or life-sciences development.+0.5

    Classifier score 0.65 · likely-financing threshold 0.60 · not a calibrated probability

    SHAB HR02-1006751691 ↗

Published by 8 Oct 2026